FierceBiotech4d
High-flying Metsera follows phase 1 weight loss data with $215M series B raise
The biotech said it would use the cash to “further accelerate” a portfolio led by its GLP-1 receptor agonist MET-097, which ...
FierceBiotech4d
Gura's weekly amylin obesity asset well tolerated, tied to weight loss in phase 1 trial
Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with a single injection also linked to weight reduction. The single ascending dose trial ...
BioSpace13d
Viking Touts Promising Phase I Weight Loss Data for Obesity Pill Candidate
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...